Preview

Эпидемиология и Вакцинопрофилактика

Расширенный поиск

Мировой опыт применения менингококковых вакцин серогруппы В (обзор литературы)

https://doi.org/10.31631/2073-3046-2021-20-6-100-107

Полный текст:

Аннотация

Актуальность. Успех вакцинопрофилактики менингококковой инфекции зависит от состава и свойств вакцинных препаратов и строгого выполнения рекомендаций по тактике ее проведения и соответствия территориальным эпидемиологическим особенностям в отношении менингококковой инфекции. Несмотря на высокое бремя В-менингококковой инфекции, особенно среди детей младшего возраста, конструирование В-менингококковых вакцин столкнулось с серьезными трудностями. Цель. В литературном обзоре представить историю создания В-менингококковых вакцин и дать характеристику двум В-менингококковым вакцинным препаратам нового поколения. Заключение. Лицензирование представленных в обзоре двух новых В-менингококковых вакцин (Bexsero и Trumenba) основывалось на их иммуногенности и безопасности. Включение вакцин в национальные программы вакцинации требует тщательного анализа, в том числе анализа антигенных характеристик циркулирующих штаммов.

Об авторах

И. С. Королева
ФБУН «Центральный научно-исследовательский институт эпидемиологии» Роспотребнадзора
Россия

Ирина Станиславовна Королева – д. м. н., заведующая лабораторией эпидемиологии менингококковой инфекции и гнойных бактериальных менингитов

Москва



М. А. Королева
ФБУН «Центральный научно-исследовательский институт эпидемиологии» Роспотребнадзора
Россия

Мария Александровна Королева – к. м. н., старший научный сотрудник лаборатории эпидемиологии менингококковой инфекции и гнойных бактериальных менингитов

Москва



Список литературы

1. American Academy of Pediatrics. Meningococcal infections. In: Kimberlin DW, Brady M, Jackson MA, Long SS, editors. Red book: Report of the 2015 committee on infectious diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:547–57.

2. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–88.

3. Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H,, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): A case-control study. Lancet Neurol. 2012;11(9):774–83.

4. Rouphael NG, Stephens DS. Neisseria meningitidis. Methods Mol Biol. 2012;799(3):1–20. PMID:21993636.

5. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369 (9580):2196–210.

6. Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73.

7. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(suppl. 2):B26–36.

8. WHO. Epidemic meningitis control in countries of the African meningitis belt, 2016. Wkly Epidemiol Rec. 2017;3(92):145–64.

9. European Center for Disease Prevention and Control. Annual Epidemiological Report 2016 – Invasive meningococcal disease 2016. [accessed 2017 Oct 1].

10. Safadi MAP, de los Monteros LEE, Lopez EL, Saez-Llorens X, Lemos AP, Moreno-Espinosa S, et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Expert Rev Vaccines. 2013;12:903–15.

11. Martin NV, Ong KS, Howden BP, Lahra MM, Lambert SB, Beard FH, et al. Communicable Diseases Network Australia MenW Working Group. Rise in invasive serogroup W meningococcal disease in Australia, 2013–2015. Commun Dis Intell Q Rep. 2016;40(4):2013–5.

12. Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM, et al. Epidemiology of invasive meningococcal b disease in Australia, 1999–2015: Priority populations for vaccination. Med J Aust. 2017;207(9):382–7.

13. Australian Government, Department of Health. Invasive menongococcal disease national surveillance report 2017. (accessed 2017 Dec 28) http://www.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/Sept-2017-IMDSurveillance-report.pdf.

14. CDC. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updatd booster dose guidance for adolescents and other persons at increased risk for meningococcal disease—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60(August (30)):1018–9

15. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010;9(March (3):285–98.

16. Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev Vaccines 2009;8(May (5):529–42.

17. Snape MD, Perrett KP, Ford KJ, John TM, Pace D,Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299(January (2)):173–84.

18. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet. 1983. 322:355–357.

19. Mandrell RE, Griffiss JM, Macher BA. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. J Exp Med. 1988;168:107–126.

20. Tsai CM, Civin CI. Eight lipooligosaccharides of Neisseria meningitidis react with a monoclonal antibody which binds lacto-N-neotetraose (Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc). Infect Immun. 1991;59:3604–3609.

21. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. 2001. Outer membrane protein vesicle vaccines for meningococcal disease, p 81–107. In Pollard AJ, Maiden MCJ (ed), Meningococcal vaccines. Humana Press, Totowa, NJ.

22. Wedege E, Kuipers B, Bolstad K, van Dijken H, Froholm LO, Vermont C, et al. 2003. Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect Immun 71:3775–3781.

23. Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 2013;9:1241–53.

24. Borrow R, Alarcon P, Carlos J, Caugant DA, Debbag R, Wals P De, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;0(0):1–16.

25. World Health Organization. Meningococcal vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(47):521–40. Available from: http://www.who.int/entity/wer/2011/wer8647.pdf?uaD1 PMID:22128384

26. Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30(suppl. 2):B10–7.

27. Masforrol Y, Gil J, Garcıa D, Noda J, Ramos Y, Betancourt L, et al. A deeper mining on the protein composition of VA-MENGOC-BC: An OMV-based vaccine against N. meningitidis serogroup B and C. Hum Vaccines Immunother. 2017;13(11):2548–60.

28. Tappero J, Lagos R, Maldonado A, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281(16):1520–7.

29. de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, et al. 2000. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18:1456–1466.

30. van den Dobbelsteen GP, van Dijken H, Hamstra HJ, Ummels R, van Alphen L, van der Ley P. 2004. From Hexamen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine, abstr P153. Abstr 14th Int Pathog Neisseria Conf, Milwaukee, WI, 5 to 10 September 2004.

31. Brehony C, Hill DM, Lucidarme J, Borrow R, Maiden MC. 2015. Meningococcal vaccine antigen diversity in global databases. Euro Surveill 20: pii 30084.http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId21330

32. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EPJ, Levels LMAR, van Dijken HH, van den Dobbelsteen GPJM. 2013. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 31:1065–1071.

33. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19(March (17–19)):2688–91.

34. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006;24(June (24)):5093–107.

35. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strainMC58. Science 2000;287(March (5459)):1809–15.

36. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287(March (5459)):1816–20.

37. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006;103(July (29)):10834–9.

38. Ladhani SN, Campbell H, Parikh SR, et al. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme. New challenges for public health. J Infect 2015;71:611–4.

39. Vernikos G, Medini D. Bexsero® chronicle. Pathog Glob Health 2014;108:305–16.

40. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:608–12.

41. MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1171–6.

42. JCVI JC on V and I. JCVI position statement on use of Bexsero meningococcal B vaccination in the UK, 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf

43. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127–37/

44. Martinón-Torres F, Carmona Martinez A, Simkó R, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect 2018;76:258–69.

45. Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its Launch. Vaccine 2019;37:4243–5.

46. European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA 2017; 2017.

47. ECDC. Vaccine Scheduler: 28. Lithuania recommended vaccines. vaccine Scheduler: Lithuania recommended vaccines, 2018. Available: https://vaccine-schedule.ecdc.europa.eu/

48. Gobierno de Canarias. Boletin Oficial de Canarias, 2019. Available at: http://www. gobiernodecanarias.org/boc/2019/126/001.html [Accessed 31 Oct 2019].

49. Boletín Oficial de Castilla Y León, 2019. Available: http://bocyl.jcyl.es/boletines/2019/04/25/pdf/BOCYL-D-25042019-41.pdf [Accessed 31 Oct 2019].

50. Govern d’Andorra. Prtoegeix ELS teus fills, 2017 Published. Available: https://www.salut.ad/images/stories/Salut/pdfs/temes_salut/Targeto_Vacunes.pdf [Accessed 31 Oct 2019].

51. Republica Di San Marino. Vaccinazioni raccomandate. Istituto per La Sicurezza Sociale, 2017. Available at: http://www.iss.sm/on-line/home/vaccini-e-vaccinazioni/vaccinazioniraccomandate.html [Accessed 31 Oct 2019].

52. Signorelli C, Chiesa V, Odone A. Meningococcal serogroup B vaccine in Italy: state-ofart, organizational aspects and perspectives. J Prev Med Hyg 2015;56:E125–32.

53. Government of South Australia, South Australian Meningococcal B expert working group. A meningococcal B program for South Australia public report, 2018. Available at: https://www.sahealth.sa.gov.au

54. Flacco ME, Manzoli L, Rosso A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. Lancet Infect Dis 2018;18:461–72.

55. Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother 2014;10:1993–2004.

56. Murdoch H, Wallace L, Bishop J, et al. Risk of hospitalisation with fever following menB vaccination: self-controlled case series analysis. Arch Dis Child 2017;102:894–8.

57. Jackson C, Yarwood J, Saliba V, et al. Uk parents’ attitudes towards meningococcal group B (menB) vaccination: a qualitative analysis. BMJ Open 2017;7:e012851.

58. Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health 2018;2:395–403.

59. De Serres G, Billard M-N, Gariépy M-C, et al. Short-Term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine 2018;36:8039–46.

60. De Serres G, Billard M-N, Gariépy M-C, et al. Nephrotic syndrome following fourcomponent meningococcal B vaccination: epidemiologic investigation of a surveillance signal. Vaccine 2019;37:4996–5002.

61. Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveill 2018;23.

62. Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine 2017;35:2034–41.

63. Ladhani SN, Giuliani MM, Biolchi A, et al. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis 2016;22:309–11.

64. Biolchi A, De Angelis G, Moschioni M, et al. 4CMenB, A Multicomponent Meningococcal Vaccine Developed for Serogroup B Meningococcu Elicits CrossReactive Immunity Also Against Serogroups C, W and Y. In: 15Th EMGM Congress. 83. Lisbon, Portugal, 2019. http://emgm2019.pt/en/content/programme/abstract-book/abstract-book.html

65. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. The Lancet 2014;384:2123–31.

66. Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine 2017;35:427–34.

67. Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. In Press 2020;382:318–27.

68. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088–2100.

69. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177:501–510.

70. Giuntini S, Reason DC, Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun. 2011;79:3751–3759.

71. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176:7566–7575.

72. Wright V, Hibberd M, Levin M. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. Vaccine. 2009;27:B90–B102.

73. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27:3417–3421.

74. Jiang H-Q, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086–6093.

75. Murphy E, Andrew L, Lee K-L, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379–389.

76. Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31:1569–1575.

77. Nissen MD, Marshall HS, Richmond PC, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2012;32:364–371.

78. Lee H. Harrison, David S. Stephens Good News and Bad News – 4CMen B Vaccine for Group B Neisseria meningitidis. The New England Journal of Medicine. 2020; 382; 4: 376–378.


Рецензия

Для цитирования:


Королева И.С., Королева М.А. Мировой опыт применения менингококковых вакцин серогруппы В (обзор литературы). Эпидемиология и Вакцинопрофилактика. 2021;20(6):100-107. https://doi.org/10.31631/2073-3046-2021-20-6-100-107

For citation:


Koroleva I.S., Koroleva M.A. World Experience in the Use Serogroup B Meningococcal Vaccines (literature review). Epidemiology and Vaccinal Prevention. 2021;20(6):100-107. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-6-100-107

Просмотров: 92


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-3046 (Print)
ISSN 2619-0494 (Online)